Kalaris Therapeutics (NASDAQ:KLRS) Upgraded by Wall Street Zen to “Hold” Rating

Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other brokerages have also issued reports on KLRS. Citigroup reissued an “outperform” rating on shares of Kalaris Therapeutics in a research note on Thursday. Citizens Jmp started coverage on shares of Kalaris Therapeutics in a report on Monday, November 3rd. They set a “market outperform” rating and a $20.00 price objective on the stock. Raymond James Financial assumed coverage on Kalaris Therapeutics in a research note on Tuesday, September 2nd. They issued a “strong-buy” rating for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kalaris Therapeutics in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Kalaris Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $11.50.

Kalaris Therapeutics Price Performance

NASDAQ KLRS opened at $9.10 on Friday. The stock has a market capitalization of $170.17 million, a P/E ratio of -2.41 and a beta of -0.04. The business has a 50 day simple moving average of $6.00 and a 200 day simple moving average of $4.34. Kalaris Therapeutics has a one year low of $2.14 and a one year high of $12.90.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.02.

Hedge Funds Weigh In On Kalaris Therapeutics

Several large investors have recently added to or reduced their stakes in KLRS. Woodline Partners LP acquired a new position in Kalaris Therapeutics during the 3rd quarter valued at about $1,394,000. Belpointe Asset Management LLC bought a new position in shares of Kalaris Therapeutics in the third quarter valued at approximately $231,000. Fortis Capital Advisors LLC purchased a new position in shares of Kalaris Therapeutics during the third quarter valued at approximately $231,000. XTX Topco Ltd bought a new stake in Kalaris Therapeutics during the second quarter worth $65,000. Finally, Bridgeway Capital Management LLC purchased a new stake in Kalaris Therapeutics in the 3rd quarter valued at $130,000. Institutional investors own 66.05% of the company’s stock.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.